Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001193125-24-258521
Filing Date
2024-11-14
Accepted
2024-11-14 16:01:49
Documents
1

Document Format Files

Seq Description Document Type Size
1 SC 13G/A d846761dsc13ga.htm SC 13G/A 38056
  Complete submission text file 0001193125-24-258521.txt   39472
Mailing Address 10955 VISTA SORRENTO PARKWAY SUITE 200 SAN DIEGO CA 92130
Business Address 10955 VISTA SORRENTO PARKWAY SUITE 200 SAN DIEGO CA 92130 (858) 751-4493
Janux Therapeutics, Inc. (Subject) CIK: 0001817713 (see all company filings)

EIN.: 822289112 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G/A | Act: 34 | File No.: 005-92596 | Film No.: 241461577
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address C/O JANUX THERAPEUTICS, INC. 11099 N. TORREY PINES ROAD, SUITE 290 LA JOLLA CA 92037
Business Address
Campbell David Alan (Filed by) CIK: 0001864158 (see all company filings)

Type: SC 13G/A